Tribulations in medicine: designing and implementing a trial of PDT plus vitamin D3 for high-grade anal dysplasia and microinvasive anal cancer (Conference Presentation)

Author(s):  
Keith A. Cengel ◽  
Timothy C. Zhu ◽  
Sally McNulty ◽  
Edgar Ben-Josef ◽  
Theresa M. Busch
Sexual Health ◽  
2007 ◽  
Vol 4 (4) ◽  
pp. 296
Author(s):  
R. Hillman

Background: Between 1970 and 2000 in Australia, anal cancer rates have increased over fourfold. Furthermore, the prevalence rate of anal cancer in MSM is approximately 35 cases/100�000, comparable to that of cervical cancer in women prior to the introduction of the national cervical screening program. These observations have led to calls for the introduction of targeted anal cytological screening program for MSMs. Our study examined the effectiveness of anal cytological testing in detecting histologically proven high grade anal intraepithelial neoplasia (HGAIN, also known as AIN2 & 3). Methods: A retrospective case note review of people attending an anal dysplasia clinic from July 2002 to May 2007 was performed. Cytological results of anal swabs were compared to results of biopsies obtained through high resolution anoscopy. Results: 436 anal cytological results were identified. Of these, 5% were unsatisfactory, 51% showed low grade changes and 44% showed high grade changes. 185 cases were then paired with corresponding histological results. Analysing the data from the perspective of diagnosing histologically proven HGAIN, anal swab cytological abnormalities revealed a sensitivity of 54% and specificity of 90% for the most recent cytological test and 83% and 39% respectively, when analysed according to most serious cytological result ever. Conclusions: Our sensitivities of 54-83% and specificities of 39-90% are consistent with those found with cervical cytology, but emphasize the need for caution in their interpretation. However, before any anal cytological screening programs are introduced, it is important to also establish that treatment of any high grade anal dysplasia detected by such screening is of value in preventing progression to cancer.


2019 ◽  
Vol 62 (8) ◽  
pp. 934-940 ◽  
Author(s):  
Yotam Arens ◽  
Michael Gaisa ◽  
Stephen E. Goldstone ◽  
Yuxin Liu ◽  
Juan Wisnivesky ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Cristina B. Sanger ◽  
Yiwei Xu ◽  
Evie Carchman ◽  
Elise Lawson ◽  
Charles Heise ◽  
...  

2020 ◽  
Vol 63 (12) ◽  
pp. 1585-1592
Author(s):  
Cristina B. Geltzeiler ◽  
Yiwei Xu ◽  
Evie Carchman ◽  
Youhi Ghouse ◽  
Jeffrey Beczkiewicz ◽  
...  

Author(s):  
E. GÖKCE ◽  
J. GELDOF ◽  
P. ROELANDT ◽  
J. VAN DORPE ◽  
S. CALLENS ◽  
...  

Early detection of precursor lesions of anal cancer in HIV-seropositive patients Although anal cancer is rare in the overall population, its incidence is increasing in the last decades. Especially HIV-seropositive patients have an increased risk of developing anal squamous cell carcinoma (SCC), mainly because of the high prevalence of high-grade anal intraepithelial neoplasia (AIN) among these patients. High-grade AIN is a precursor lesion for anal SCC associated with human papillomavirus (HPV) infection. Despite the lack of direct evidence demonstrating that AIN identification reduces the risk of anal cancer, experts think that screening and treatment of high-risk patients will prevent the disease. This article aims to review the current literature about AIN and discusses the screening options, including digital rectal examination, anal cytology and high-resolution anoscopy.


2018 ◽  
Vol 98 (6) ◽  
pp. 616-617
Author(s):  
A Kreuter ◽  
M Hufbauer ◽  
S Silling ◽  
F Oellig ◽  
B Akgül ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. S-413-S-414
Author(s):  
Alexander O. Mallari ◽  
Theresa Schwartz ◽  
Emmanuel C. Gorospe ◽  
Amneris Luque ◽  
Stephen Rauh ◽  
...  

2019 ◽  
Vol 70 (6) ◽  
pp. 1121-1128
Author(s):  
Cecile D Lahiri ◽  
Minh Ly Nguyen ◽  
C Christina Mehta ◽  
Marina Mosunjac ◽  
Talaat Tadros ◽  
...  

Abstract Background Anal cancer rates have increased, particularly in human immunodeficiency virus (HIV)–infected (HIV+) women. We assessed factors associated with anal precancer in HIV+ and at-risk HIV-negative women from the Atlanta Women’s Interagency HIV Study cohort. Methods All participants underwent high-resolution anoscopy and anal cytology and had anal and cervical samples collected. Specimens were tested for 37 human papillomavirus (HPV) types and for FAM19A4 and microRNA124-2 promoter methylation. Binary logistic regression and multivariate analysis were conducted with histologic anal high-grade squamous intraepithelial lesion (A-HSIL) as the dependent variable. Results Seventy-five women were enrolled: 52 (69%) were HIV+ with three-fourths having undetectable viral load; 64 (86%) were black; mean age was 49 ± 8 years. Forty-nine (65%) anal cytology samples were abnormal, and 38 (51%) of anal samples were positive for at least 1 of 13 high-risk HPV (hrHPV) types. Thirteen (18%) anal biopsies identified A-HSIL. Hypermethylation of FAM19A4 and/or microRNA124-2 was found in 69 (95%) anal samples and 19 (26%) cervical samples. In multivariate analyses, the odds of having A-HSIL were >6 times higher in women with anal hrHPV (adjusted odds ratio [aOR], 6.08 [95% confidence interval {CI}, 1.27–29.18], P = .02) and with positive cervical methylation (aOR, 6.49 [95% CI, 1.66–25.35], P = .007), but not significantly higher in women with positive anal methylation. Conclusions Anal hrHPV and promoter hypermethylation in the cervix show promise as biomarkers for anal cancer screening in HIV+ and at-risk HIV-negative women. Greater understanding of gene silencing by promoter hypermethylation in anal carcinogenesis is needed.


Sign in / Sign up

Export Citation Format

Share Document